Spondyloarthritis & psoriatic arthritis
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab
Authors' conclusion
These analyses support the validity of 3VAS/4VAS as multidimensional measures of PsA disease activity.
Study context
- Population
- Participants with psoriatic arthritis (PsA) treated with guselkumab in the DISCOVER-1, DISCOVER-2 and COSMOS phase III RCTspooled from 3 RCTs
- Participants
- 1,405 participants
- Comparison
- 3VAS vs 4VAS
- Primary endpoint
- Validity of 3VAS and 4VAS; MCID and MDC for each measure
Methodological detailspsychometric validation study, pooled data from DISCOVER-1, DISCOVER-2 and COSMOS, ROC curve analysis, mixed models
- Psychometric validation study
- Pooled data from DISCOVER-1, DISCOVER-2 and COSMOS
- ROC curve analysis
- Mixed models
Primary result
As reported in the abstract
Validity, MCID, MDC and disease activity cutoffs of 3VAS/4VAS
| Group | Minimal clinically important difference (MCID) | MCID range by method | Minimal detectable change (MDC) | Cutoff low disease activity | Cutoff moderate disease activity | Cutoff high disease activity | Correlation with HAQ-DI | Correlation with PGA |
|---|---|---|---|---|---|---|---|---|
| 3VAS | 0.9 | 0.7-1.3 | 3.1 | 2.1 | 3.3 | 4.8 | 0.56 | 0.92 |
| 4VAS | 0.9 | 0.6-1.3 | 3.0 | 2.1 | 3.4 | 5.0 | 0.62 | 0.94 |
Minimal clinically important difference (MCID)
3VAS0.9
4VAS0.9
MCID range by method
3VAS0.7-1.3
4VAS0.6-1.3
Minimal detectable change (MDC)
3VAS3.1
4VAS3.0
Cutoff low disease activity
3VAS2.1
4VAS2.1
Cutoff moderate disease activity
3VAS3.3
4VAS3.4
Cutoff high disease activity
3VAS4.8
4VAS5.0
Correlation with HAQ-DI
3VAS0.56
4VAS0.62
Correlation with PGA
3VAS0.92
4VAS0.94
Further findings
Association of change in 4VAS at week 8 of guselkumab with change in PsA-modified Sharp-van der Heijde (SvdH) score through week 100
- Change in 4VAS at week 8 significantly associated with change in SvdH score through week 100
- P = 0.04
Original publication
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab. J Rheumatol. Published 1 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →